R
adiotherapy of cancer cells using cytotoxic radionuclides has wide application in basic research and clinical practice (1, 2) . Antibody-and peptide-based radiotherapy agents have the advantages of specifically and selectively targeting cancer cells through overexpressed or unique antigens or receptors. Most success with antigen-based agents has been in treating hematological malignancies (3, ʈ) . However, these agents have only limited clinical success in treating solid tumors because of heterogeneous antigen expression among tumor cells and low overall tumor uptake.
Tumor resistance to therapy can be correlated , in part, to the development of hypoxic regions (areas of low oxygen tension; ref. 4 ). Hypoxic areas have been shown to be resistant to traditional chemotherapy because of hypoxia's effects on induced genes and by reducing the ability of the drug to create oxygen free radicals (5-7), which also protects from lethal effects of conventional ionizing radiation therapy (5, 6) . However, high linear electron-transfer radiation such as ␣ particles can kill cells effectively independent of cellular oxygenation. Creating hypoxia-selective small molecules, labeled with useful emissions, would provide a noninvasive method to treat resistant tumors. It is proposed that delivery of 64 Cu to a hypoxic cell could have such an effect because of its decay properties.
A number of metal-based small molecules have been suggested as agents for cancer radiotherapy. For example, metaloxime chelates with 99m Tc, 186 Re, 188 Re, 67 Cu, and 107 Ag (8) and rhenium-labeled hormones (9) have been suggested, but no preclinical or clinical data have been reported. This current work details an approach using dithiosemicarbazone complexes of radioactive Cu. The antitumor properties of dithiosemicarbazones were discovered in the 1960s (10) , and the antitumor activity of the Cu(II) complexes of these ligands was greater than the ligands alone (11) . With Cu radioisotopes, these neutral lipophilic Cu(II)bis(thiosemicarbazones) demonstrated rapid diffusion into cells and trapping of Cu ions (12, 13) . Evaluation in vitro and in vivo showed uptake that is either nonhypoxiaselective (e.g., Cu-pyruvaldehyde-bis(N 4 -methylthiosemicarbazone) or hypoxia-selective [e.g., 64 Cu-diacetyl-bis(N 4 -methylthiosemicarbazone) (Cu-ATSM)] (14-16). These agents, labeled with copper radionuclides, have been evaluated as radiopharmaceuticals for myocardial and cerebral perfusion imaging, delineating hypoxia with positron-emission tomography (PET) and examining mitochondrial dysfunction (12, 14, 15, 17) . The hypoxia selectivity of Cu-ATSM ( Fig. 1 ) has been proven in vivo in animal tumor models (14) , and preliminary clinical studies with 60 Cu-ATSM show it to be a noninvasive selective diagnostic marker for hypoxia in human cancers.** , † †, ‡ ‡ Copper-64 [t 1͞2 ϭ 12.7 h; E ␤ϩmax ϭ 0.653 million electronvolts (MeV) (17.4%); E ␤Ϫmax ϭ 0.574 MeV (40%)] is a readily available cyclotron-produced positron-emitting isotope (18) with utility in diagnostic medicine (19) and promise as a therapeutic radionuclide because of its favorable ␤ Ϫ particle emissions (20, 21) . It possesses similar lethality to 67 Cu whether free or complexed (22, 23) . Agents based on Cu(II)-bis(thiosemicarbazone) complexes, which are taken up into tumor cells rapidly and efficiently, would have potential as radiotherapeutic agents in cancer. Additionally, 64 Cu labeling allows accurate assessment of tumor dosimetry and treatment response by using PET.
64
Cu-ATSM is taken up into hypoxic cells preferentially over normoxic cells in tumors (14) . As a consequence, there may be greater cell killing of the hypoxic cells within a tumor. The levels of hypoxia in tumors can be manipulated by using hydralazine, a vasodilator that increases blood flow to most organs but decreases blood flow to tumors, transiently and dramatically decreasing tumor oxygenation (24, 25) . Because hydralazine increases tumor hypoxia, it also may improve retention of Cu-ATSM, leading to a greater therapeutic response compared with nonhydralazine treated tumors. This present study addresses these hypotheses and evaluates the therapeutic efficacy of hypoxia-selective 64 Cu-ATSM in colorectal cancer by using a tumor-bearing hamster model with and without hydralazine.
Materials and Methods

64
Cu was produced on a CS-15 biomedical cyclotron at Washington University School of Medicine by using reported methods (18) . 64 Cu-ATSM was synthesized by using previously described methods (16) . All chemicals, unless otherwise stated, were purchased from Aldrich. All solutions were prepared by using distilled deionized water (Milli-Q, Ͼ18 M⍀ resistivity; Millipore). Radiochemical purity of 64 Cu-ATSM in all studies was Ͼ98%.
Animal Models. Animal experiments were conducted in compliance with the Guidelines for the Care and Use of Research Animals established by Washington University's Animal Studies Committee. Male Golden Syrian hamsters (7 to 9 weeks old; Sasco Inc., Omaha, NE) were implanted with GW39 human colorectal carcinoma tumors in the thigh muscle as described (23) . Animals were injected with vehicles or a tracer by cardiac puncture whilst under halothane anesthesia. Cardiac-puncture administration in hamsters has been adopted in our facilities and permits comparison to previous agents. In some animals, hydralazine was administered intraperitoneally 1 h before radioactivity at 5 mg͞kg in a saline vehicle (1 mg͞ml) to increase hypoxia transiently within the tumor before administration of radioactivity.
Therapy Studies. Radiotherapy experiments were performed in animals bearing either 7-day-old (0.5-1.0 g) or 15-day-old (1.5-2.0 g) tumors. Studies compared animals treated with a single administration of 0, 4, 6, 7, 8, or 10 mCi of 64 Cu-ATSM (1 Ci ϭ 37 GBq) with or without hydralazine. The first study followed the survival of three groups of animals with 7-day-old tumors, which were those that received only hydralazine, only 10 mCi of 64 Cu-ATSM, or hydralazine plus 10 mCi of 64 Cu-ATSM. Another similar study tested a multiple-dose regimen of 3 ϫ 4 mCi at 72-h intervals. A third study in animals with 7-day-old tumors compared the efficacy of 6, 8, or 10 mCi of 64 Cu-ATSM with no hydralazine. A similar dose-titration study with 15-day-old tumors was done to determine the radioactivity required to increase survival significantly. Throughout the experiment with 7-day-old tumors treated with 10 mCi of 64 Cu-ATSM, the tumor volume was monitored by direct calculation of the tumor volume by MRI. Each study was ended at 135 days after drug administration or a tumor burden of 10 g, whichever occurred earlier.
Statistical Analysis. To compare survival among different treatment groups, the SAS Lifetest procedure (26) was used to generate Kaplan-Meier probability density plots, and these data then were analyzed by using log-rank, Wilcoxon test, and Ϫ2log (LR) statistics and the P values are reported. Survival of each group at 135 days after injection was compared, and P Ͻ 0.05 was considered significantly different.
Toxicity. The Diagnostic Services Laboratory in the Department of Comparative Medicine at Washington University School of Medicine performed toxicity analyses. Physical appearance and hematologic, liver, and kidney chemistries for the tumor-bearing hamsters that received 10 mCi of 64 Cu-ATSM were compared with those from hamsters treated with control agents. The hematology analysis included total protein, hemoglobin, white blood cell counts (WBCs), red blood cell counts, platelet counts, hematocrit, and differential WBCs. Liver and kidney analysis included blood urea nitrogen, creatinine, alanine aminotransferase, and aspartate aminotransferase counts. The tumors were examined histologically at 135 days ex vivo by using hematoxylineosin and Mucin-staining techniques (27) .
MRI and PET Imaging. Response to 64 Cu-ATSM treatment was monitored weekly by using T 2 -and diffusion-weighted MRI. In four animals with 7-day-old tumors, 10 mCi of 64 Cu-ATSM was injected by cardiac puncture after the baseline T 2 -weighted MRI. Then, 10-min static PET imaging was performed on a Siemens ECAT EXACT HR ϩ Scanner 24 and 48 h after injection. This scanner has a large axial field of view (15.52-cm) with a spatial resolution of 4.5 mm full-width half-maximum at center. The field of view is sectioned into 63 transaxial planes. The MRI protocol was performed at days 1, 2, and 7 days and weekly afterward for 8 weeks on an Oxford Instruments 200͞330 (4.7 tesla, 33-cm clear bore) magnet equipped with a 16-cm inner diameter actively shielded gradient coil (18 G͞cm, 400-sec rise time). The magnet, gradient coil, and power supply were interfaced with a Varian UNITY-INOVA console controlled by a Sun Microsystems Ultra-170 SPARC workstation (TE ϭ 50 msec, TR ϭ 3 sec, field of view ϭ 4 ϫ 4 cm, 1-mm slice, 256 ϫ 256 pixels). The entire tumor mass was measured regardless of whether tissue was necrotic or healthy.
Dosimetry. Estimated human-absorbed doses of 64
Cu-ATSM to normal organs were calculated by using biodistribution data in nontumor-bearing hamsters according to described methods (21, 28) . 64 Cu-ATSM (35 Ci, 1.3 MBq) was injected by cardiac puncture, and the hamsters were killed at 1, 3, 6, 12, 24, 36, or 48 h after injection. Animals for the 48-h time point were housed in metabolism cages to determine percentage of injected dose excreted in urine and feces at 1, 3, 6, 17, 24, 43, and 48 h. Time-activity curves (TACs) were generated for 12 organs. Cumulative activity (Ci͞h or kBq͞h) was determined by calculating the area under the TACs. Human-dose estimates then were calculated by using standard medical internal-radiation dose techniques, and S-values (mean absorbed dose per unit cumulative activity) for 64 Cu were obtained from the MIRDOSE3 program (29) . Bone activity was assumed to be distributed equally between the trabecular bone and cortical bone.
Tumor Dosimetry. The absorbed dose to the GW39 tumor was determined from biodistribution data and by PET imaging. In the biodistribution method, tumor-uptake values from all time points after injection were combined by using integration methods to provide time-activity data. A nontherapeutic amount of 64 Cu-ATSM (5 Ci) was administered to hamsters bearing 7-day-old GW39 tumors. At selected time points over 48 h (n ϭ 5), each tumor was excised and weighed, and an S value was interpolated by using a power function fitted through S values calculated with MIRDOSE3 for spherical nodules of standard sizes (28) . S values and absorbed fractions were in agreement with a reported result (23) . The tumor S values were calculated also by an electron-transport calculation (EGS4) and were in close agreement with those calculated by the MIRDOSE3 method above. Although alternative methods exist for calculating tumor dosimetry, it was preferable in this study to use MIRDOSE3 to simplify comparison with other previously reported 64 Cu-agents tested in the GW39 tumor model. In the PET-plus-MRI study, hamsters bearing 7-day-old tumors (n ϭ 4) were injected with a therapeutic amount of 64 Cu-ATSM (10 mCi) and were imaged by PET (10-min collection) and MRI (see above) at four time points over 48 h. Total uptake of 64 Cu-ATSM in the tumor was determined directly from the images by using reported methods and volume-ofinterest techniques (28, 30) . Tumor weight in each animal was determined by MRI assuming a tumor density of 1.04 g͞cm 3 . Then tumor S values were calculated with MIRDOSE3 nodule module as described above. Tumor dose was determined for each animal, and the weighted average was calculated.
Results
Therapy Studies. Therapy results are summarized in Fig. 2 . Administration of 10 mCi of 64 Cu-ATSM to animals bearing 7-day-old tumors caused a 6-fold increase in survival (135 days) in 50% of the hamsters compared with controls (20 days, P ϭ 0.002) (Fig. 2 A) . When compared with controls, a significant survival increase was seen also in the 10-mCi-of-64 Cu-ATSM and hydralazine group (P ϭ 0.0002). However, survival time of 64 Cu-ATSM-treated animals was not affected by pretreatment with hydralazine (P ϭ 0.589).
64
Cu-ATSM administered 3 ϫ 4 mCi in 72-h intervals (Fig. 2B ) also improved survival significantly compared with controls (P ϭ 0.0001), but again hydralazine did not affect survival time (P ϭ 0.986). In the first dose-titration study with 7-day-old tumors ( Fig. 2C) , there was no significant difference in survival for 6 or 8 mCi of 64 Cu-ATSM (P ϭ 0.665), although both were significantly better than controls (6 mCi, P ϭ 0.014; 8 mCi, P ϭ 0.005). However, 10 mCi was superior compared with all groups (6 mCi, P ϭ 0.002; 8 mCi, P ϭ 0.007; controls, P ϭ 0.001). In 15-day-old tumors ( Fig. 2D) , a dose of Ͼ6 mCi significantly increased survival time compared with controls (P ϭ 0.001). All data sets were examined by using a regression analysis with the delivered dose as a continuous variable. The slope generated from this analysis was positive, indicating the trend that life expectancy increased with dose. Administration of H 2 -ATSM or nonradioactive Cu-ATSM in amounts equivalent to those in the radioactive studies resulted in identical survival to the vehicle and hydralazine controls (data not shown).
Toxicity. Animals receiving 10 mCi of 64 Cu-ATSM displayed a transient depression in white blood cell count (WBC) and platelets. Toxicity was monitored further by weight loss and gross physical appearance, as well as hematologic, liver, and kidney function. The mean weight of the treated hamsters increased similarly to that of the control hamsters, and they maintained a healthy physical appearance (with no sign of scruffy coat or diarrhea) over the experimental period. Throughout the examination period, there were no significant changes in the total protein, hemoglobin, or red blood cell counts in any of the experimental or control groups. A 60% average decrease in WBC was noted after 3 days (4,530 Ϯ 970͞mm creased by 52 and 49% of controls, respectively, by day 3 after treatment but returned to baseline by day 8.
Histological examination (hematoxylin-eosin and Mucin staining) of tissue remaining at the site of tumor implantation exhibited extensive necrosis. Cu-ATSM localized in the GW39 tumor 24-h after administration (Fig. 3A) . Position of the tumor mass was confirmed by T 2 -weighted MRIs of the same hamster in the same plane. Abnormal tissue ''tumor-like mass'' was still present 8 weeks after treatment, but volume was not significantly different from day 1 after treatment. Animals receiving no treatment were killed by 4 weeks because of tumor burden (Fig. 3B) . Increased signal intensity was observed in the T 2 -weighted MRI beginning at day 1 after treatment. On day 36 after treatment, the T 2 -weighted images showed changes in tumor heterogeneity: a ''pitted'' appearance suggestive of a fibrotic response appears (Fig. 3C) . Ex vivo histological examination of this abnormal mass showed edema, lymphocyte infiltration, and extensive necrosis. Cu-ATSM in hamsters with 7-day-old tumors was determined by two methods: biodistribution and PET imaging plus MRI. The maximum uptake of 64 Cu-ATSM into the GW39 tumor was 2.71 Ϯ 0.26% injected dose per g at 4 h. When using data obtained from nontherapy biodistribution studies, the estimated therapeutic (10 mCi) dose delivered to the GW39 tumor was 57 Ϯ 30 rad͞mCi (15.4 Ϯ 8.1 mGy͞MBq). When extrapolating data obtained from PET and MRI of a therapeutic administration of 10 mCi of 64 Cu-ATSM, the tumor dose was similar at 81 Ϯ 7.5 rad͞mCi (21.9 Ϯ 2.1 mGy͞MBq; P ϭ 0.12).
Discussion
64
Cu has been used for PET imaging (30, 31) and for radiotherapy (21, 23, 28) . 64 Cu-labeled mAb 1A3 has similar lethality to 67 Cu-labeled mAb 1A3, and both Cu-labeled agents clearly exhibited complete tumor-growth inhibition in the established and widely used GW39 animal model of colorectal cancer (27) . 64 Cu-labeled somatostatin-based peptides were taken up significantly in somatostatin-rich tissues in two tumor-bearing animal models and caused regression of CA20948 pancreatic tumors in rats (21, 28) . Agents based on Cu(II)bis(thiosemicarbazone) complexes bypass the more common problems associated with using radiolabeled antibodies, with which success in treating solid tumors has been limited, because poor tumor uptake requires therapeutic doses that result in hematopoietic suppression (32, 33) . The current investigation reports the therapeutic effectiveness of the hypoxia-selective agent 64 Cu-ATSM in a hamster tumor-bearing model. The results clearly demonstrate that 64 Cu-ATSM significantly increased survival of GW39 tumor-bearing hamsters compared with controls. This increase is impressive considering that GW39 tumors are not very responsive to a number of anticancer drugs and external X-irradiation (34), similar to human colorectal cancer. In addition, toxicity data indicate that the maximum tolerated dose (MTD) for this compound was not achieved, and larger quantities of radioactivity could be administered safely. Therefore, significant survival benefit was seen with less than the MTD of 64 Cu-ATSM. In all control groups, tumor burden reached the experimental endpoint of 10 g by 4 weeks. In contrast, in all animals receiving a dose greater than 6 mCi of 64 Cu-ATSM, tumor growth was inhibited and survival increased (Fig. 2) . Animals with 7-day-old tumors receiving 10 mCi of 64 Cu-ATSM (Ϯ hydralazine) had a 50% survival rate at the 4-month experimental end point (merged data, Fig. 2 A and C) .
Although it could be argued that larger tumors would have more hypoxic tissue and would therefore respond better than smaller tumors, survival at 4 months was just 30% when initial tumor burden was 1.5-2.0 g (15-day-old tumors; Fig. 2D ). There are a number of possible explanations for this response. First, the larger tumor volume may reduce the effective concentration of 64 Cu-ATSM in hypoxic regions because of larger regions of necrosis leading to poor vascularization restricting the delivery of the agent to subtherapeutic levels. Further, 64 Cu emits a 0.58-MeV ␤ Ϫ particle (40%), a 0.66-MeV ␤ ϩ particle (19%), and a ␥ of 1.34 MeV (0.5%), giving a mean range of penetrating radiation of less than a millimeter in tissue; thus, 64 Cu emissions are more suitable for smaller tumor masses unless uniform distribution throughout the tissue is achieved.
In the multiple-dose protocol using 64 Cu-ATSM, overall survival was similar to the single-dose administration of 10 mCi and significantly longer than controls. Advantages of multiple-dose regimens over single-dose protocols have precedence in radioimmunotherapy (35, 36) and radiotherapy with peptides (28, 37) . Fractionated doses deliver radiation over an extended period, which allows intermittent recovery of nontarget tissues, significantly reducing toxicity and increasing the tolerated tumor dose. However, the results presented here suggest the multiple-dose protocol and a 10 mCi single dose have similar effectiveness. Again, there are a number of possible explanations. First, the initial treatment in the multiple-dose regimen may kill significant amounts of the hypoxic regions. Because tumor volume remains static and new hypoxic region formation is unlikely, there could be relatively less hypoxia during subsequent doses, reducing their effectiveness. Furthermore, a different multidosing protocol may prove more effective than the single 10 mCi dose, which itself is not the maximum tolerated dose. To improve on the results reported here, optimization could be achieved by altering the dosing-time interval by using Cu-ATSM (labeled with the positron-emitting 60 Cu, 61 Cu, or 64 Cu) to delineate tumor hypoxia with PET and monitor changes in the hypoxic extent of tumors. After the first therapeutic dose, PET imaging will be performed regularly to determine when hypoxic levels are again significant. The next therapeutic dose of 64 Cu-ATSM then would be given, and so on. Studies with a needle oxygen electrode have shown a decrease in tumor oxygenation after treatment with hydralazine (38) . However, the current study showed that pretreatment with hydralazine did not increase survival significantly compared with nonhydralazine groups. It was expected that hydralazineinduced transient hypoxia would improve the therapeutic effectiveness of 64 Cu-ATSM. It is unclear why therapeutic effectiveness did not increase, but several confounding factors exist, including the vasodilatory effect in normal tissues reducing delivery of 64 Cu-ATSM to the tumor and the length of action of the drug. Additionally, altered pharmacokinetics of 64 Cu-ATSM following hydralazine treatment may contribute to these findings (38) .
The human-absorbed dose estimates calculated from hamster biodistribution data show lower large intestine (LLI) and upper large intestine (ULI) to be the dose-critical organs, primarily because of hepatobiliary excretion. Comparison of the calculated doses for 64 Cu-ATSM and 64 Cu-TETA-1A3 is in Table 1. The  calculated   64 Cu-ATSM absorbed doses to the hepatobiliary system are higher than those for 64 Cu-TETA-1A3, but other nontarget organs such as kidney and bone are lower than for the antibody. In the present therapeutic study, a single dose of 10 mCi 64 Cu-ATSM was administered to tumor-bearing hamsters, which weighed approximately 100 g, suggesting a dose of 7,500 mCi of 64 Cu-ATSM for clinical therapy trials in humans. This extrapolates to absorbed doses of 10,725 rad (107.25 Gy) to LLI wall, 9,007 rad (90.07 Gy) to ULI wall, and 5,197 rad (51.97 Gy) to liver. Fractionation might reduce the absorbed doses to nontarget organs significantly by allowing the delivery of a consistent amount of tolerable radiation over an extended period to the tumor, while allowing intermittent recovery of nontarget tissues. Laxatives can also be used to help reduce the absorbed doses to the intestines. It is also important to note that hepatobiliary and renal clearance of many radiopharmaceuticals vary widely from rodents to humans (39) , and primate and human data may improve dose estimates.
The dose of 64
Cu-ATSM to 7-day-old tumors was calculated in two ways: by biodistribution studies and PET plus MRI. Biodistribution experiments performed with a nontherapeutic tracer level of radioactivity result in continued tumor growth throughout the study, whereas in therapy studies, tumor volumes are static or decrease. Because tracer biodistribution may differ from biodistribution of therapeutic quantities, using tracer biodistribution data could estimate tumor dose delivered in a therapy study inaccurately. From biodistribution data, we calculated a tumor dose of 57 Ϯ 30 rad͞mCi (15.4 Ϯ 8.1 mGy͞ MBq). PET plus MRI with a therapeutic amount of radioactivity (10 mCi) gave a tumor dose of 81 Ϯ 7.5 rad͞mCi (21.9 Ϯ 2.1 mGy͞MBq). Although these values are not significantly different (P ϭ 0.12), using PET plus MRI allowed us to calculate tumor dose from a therapeutic administration and monitor tumor volume over time, which may produce a more realistic tumor dose of 64 Cu-ATSM. Monitoring tumor volume during therapy allows tumor-absorbed doses to be calculated individually before averaging, a situation not possible in biodistribution.
The tumor dose of 81 Ϯ 7.5 rad͞mCi (21.9 Ϯ 2.1 mGy͞MBq) for 64 Cu-ATSM is lower than the dose of 110 rad͞mCi (29.7 mGy͞rad) calculated for radioimmunotherapy of smaller GW39 tumors with 3 mCi of 64 Cu-labeled 1A3 (23) . Another study showed that 7 mCi of internalizing 64 Cu-labeled 1A3 (770 rad, 7.7 Gy) gave 40% survival (8 of 20) 4 months after treatment of 7-day-old tumors (40) , comparable to the current study (merged data, Fig. 2 A and C Cu decays 40% by electron capture, emitting Auger electrons with high linear electron transfer. Radiotoxic Auger electrons have a tissue penetration of 0.02-10 m with very high toxicity if the DNA of the cell is within range (45) . 64 Cu emits a 6.84-keV Auger electron with a penetration range of about 5 m, the approximate cell-nucleus diameter. Moreover, the maximum recoil energy from the transmutation of 64 Cu (from ␤ Ϫ ϭ 7.6 eV; from ␤ ϩ ϭ 9.15 eV) (46) to its highly charged daughter nucleus may also increase the cell-killing ability. The combination of these characteristics with the likely event 64 Cu is bound to certain structures within the nucleus increase its toxicity. Additionally, Auger-and recoil-linked toxicity would be as great in hypoxic cells as in oxygenated.
Because low-energy Auger electrons deposit their energy in a very small volume and the 64 Cu is likely very close to DNA, conventional macroscopic dose calculations are likely to underestimate the energy imparted and thus the dose. A microdosimetric approach to the tumor-dose calculations, accounting for all Auger electrons, would raise estimates and relate more closely to the observed growth inhibition. Because of their short-range and relatively larger linear electron transfer, low-energy Auger electrons potentially are more radiotoxic than the higher-energy positron or ␤ Ϫ particle. The PET plus MRI yielded information and data not normally available in radiotherapy experiments in rodents. Historically, tumor volumes have been calculated from caliper measurements. However, they provide no physiologic information during radiotherapy experiments, and their accuracy is limited by tumors' irregular shapes. In this study, MRI confirmed and quantified tumor mass and also indicated severe necrosis and a long reabsorption time. Caliper methods alone would have given incomplete information. Our results indicate PET plus MRI can help to monitor therapeutic response, determine overall treatment effectiveness, and permit accurate dosimetry calculations.
Radiotherapeutic effectiveness depends on radioligand delivery to, and accumulation in, the cell. Therefore, high accessibility and up-regulation of antigens or receptors is required for effective treatment by using peptide-or antibody-based agents but not 64 Cu-ATSM or other nonreceptor-based agents. Therapeutic quantities of hypoxia-selective 64 Cu-ATSM inhibited GW39 tumor growth in hamsters and significantly increased survival with no acute toxicity. The addition of 64 Cu to the radiotherapy arsenal is useful and innovative because it enables accurate monitoring of drug distribution and biokinetics through concurrent PET imaging. 64 Cu-ATSM has shown exceptional promise as a radiotherapy agent and could be used before, during, or after surgery to ablate ''resistant'' tumor regions before traditional treatments.
